瑞波西利联合非甾体芳香化酶抑制剂辅助治疗高危HR+/HER2-早期乳腺癌的六年总生存随访:NATALEE试验
BACKGROUND: Ribociclib plus nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) earl…
要点
- 瑞波西利联合NSAI在NATALEE eligible人群中显示OS获益,6年ΔOS 2.1%。
- iDFS获益随时间增加,6年ΔiDFS 5.3%,HR 0.741。
- DDFS和DRFS结果支持OS和iDFS获益,安全性无新信号。
核心结论
- 瑞波西利联合NSAI辅助治疗在高危HR+/HER2-早期乳腺癌中显示具有临床相关性的OS获益,与复发风险持续降低一致。
研究设计与样本
- NATALEE是一项3期随机对照试验,入组成人HR+/HER2-早期乳腺癌患者,解剖学分期为IIA(N1或N0伴高危因素)、IIB或III期。
- 患者按1:1随机接受瑞波西利400 mg/天(服3周停1周,共3年)联合NSAI(来曲唑2.5 mg/天或阿那曲唑1 mg/天,共5年)或单用NSAI;绝经前女性和男性同时接受戈舍瑞林。
- 主要终点为iDFS,次要/探索性终点包括OS、DDFS和DRFS;本次为预设的6年分析。
主要发现
- DDFS(HR 0.744,95%CI 0.646-0.858)和DRFS(HR 0.738,95%CI 0.634-0.858)结果支持上述发现。
- OS和iDFS获益在关键亚组中总体一致。
- 未观察到新的安全性信号。
临床怎么用
- 对于NATALEE eligible的高危HR+/HER2-早期乳腺癌患者,辅助瑞波西利联合NSAI可作为改善长期生存的治疗选择。
局限性
- OS分析为预设的描述性分析,P值为名义单侧检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ribociclib plus nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at the primary efficacy analysis of the phase 3 NATALEE trial. This prespecified 6-year analysis assessed overall survival (OS) and other efficacy outcomes as well as safety. PATIENTS AND METHODS: Eligible patients were adults with HR+/HER2- EBC and anatomic stage IIA (N1 or N0 with high-risk factors), IIB, or III disease. Enrolled patients were randomized 1:1 to ribociclib 400 mg/day (3 weeks on/1 week off for 3 years) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 5 years) or NSAI alone. Premenopausal women and men also received goserelin. The primary endpoint was iDFS, and secondary/exploratory endpoints included OS, distant disease-free survival (DDFS), and distant recurrence-free survival (DRFS). RESULTS: With a median OS follow-up of 66.5 months, ribociclib plus NSAI demonstrated an OS benefit over NSAI alone (6-year ΔOS, 2.1%; HR, 0.809 [95% CI: 0.661-0.989]; nominal 1-sided P = .019), which was generally consistent across key subgroups. An increasing iDFS benefit with ribociclib plus NSAI was also observed (6-year ΔiDFS, 5.3%; HR, 0.741 [95% CI: 0.646-0.849]; nominal 1-sided P < .0001), which was also generally consistent across key subgroups. DDFS (HR, 0.744 [95% CI: 0.646-0.858]) and DRFS (HR, 0.738 [95% CI: 0.634-0.858]) results supported these findings. No new safety signals were observed. CONCLUSIONS: This prespecified descriptive 6-year OS analysis demonstrated positive OS results with a clinically relevant benefit of ribociclib plus NSAI, consistent with the increasing reduction in recurrence risk. These results reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population. CLINICAL TRIAL REGISTRATION: NCT03701334 (ClinicalTrials.gov).
引用
- Slamon DJ, Hortobagyi GN, Stroyakovskiy D, et al. Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial. Ann Oncol. 2026. PMID: 42918423. doi:10.1016/j.annonc.2026.10.1288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。